Eton Pharmaceuticals (ETON) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 172.2% versus a loss of 51.1%. Over five years, ETON leads with a +959.7% price change compared with -80.7% for RARE. Eton Pharmaceuticals is the larger company by market cap ($1.58 billion vs $1.53 billion), about 1.0 times the size.
On valuation, Eton Pharmaceuticals trades at a lower forward P/E (21.4x vs 22.9x for Ultragenyx Pharmaceutical). Eton Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.8% versus -85.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | RARE |
|---|---|---|
| Share price | $55.21 | $15.48 |
| Market cap | $1.58B | $1.53B |
| 1-day change | +0.84% | +1.24% |
| YTD return | +226.49% | -32.70% |
| 1-year return | +172.24% | -51.11% |
| 5-year return | +959.69% | -80.65% |
| P/E ratio (TTM) | 138.03 | — |
| Forward P/E | 21.40 | 22.87 |
| EPS (TTM) | $0.40 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $79.95M | $673.00M |
| Revenue growth (YoY) | +104.94% | +20.18% |
| Net income (latest FY) | $-4.60M | $-575.00M |
| Gross margin | 53.46% | — |
| Operating margin | -1.06% | -79.49% |
| Net margin | -5.75% | -85.44% |
| 52-week high | $66.37 | $39.89 |
| 52-week low | $14.27 | $12.73 |
| Distance from 52-week high | -16.81% | -61.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +28.60% | +73.06% |
| Average volume | 611.24K | 3.89M |
| Shares outstanding | 28.58M | 98.59M |
| Employees | 44 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed RARE by 223.3 percentage points over the past year.
- Eton Pharmaceuticals is more profitable, keeping -5.8 cents of every revenue dollar as net income versus -85.4 cents for Ultragenyx Pharmaceutical.
- Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs +20.18%).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
ETON vs RARE FAQ
Which is bigger, Eton Pharmaceuticals or Ultragenyx Pharmaceutical?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.58B compared with $1.53B for Ultragenyx Pharmaceutical (RARE).
Which stock has performed better over the past year, ETON or RARE?
ETON returned +172.24% over the past 12 months, compared with -51.11% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.